Senseonics Holdings, Inc.
Business
Senseonics Holdings, Inc. is a medical technology company that develops and commercializes Eversense, a long-term implantable continuous glucose monitoring (CGM) system for diabetes management. The Eversense product line includes the Eversense 365 (approved by FDA in September 2024 for up to 12 months of wear) and Eversense E3 (approved for up to 6 months), both offering longer duration than non-implantable CGM systems. The company distributes directly through healthcare providers, strategic partners, and third-party distributors in the United States and European markets, with the company assuming direct commercial responsibility in the U.S. as of January 2026.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue, net | 35 | 22 | 22 | 16 | 1 | |
| Cost of sales | 19 | 22 | 19 | 14 | 14 | |
| Gross profit | 16 | 533,000 | 3 | 3 | −811,000 | |
| Research and development expenses | 32 | 41 | 49 | 40 | 27 | |
| Selling, general and administrative expenses | 53 | 34 | 30 | 32 | 29 | |
| Operating loss | −68 | −75 | −76 | −69 | −57 | |
| Interest income | 4 | 5 | 5 | 2 | 243,000 | |
| Interest expense | −5 | −8 | −11 | — | — | |
| Gain on change in fair value of derivatives | — | 102,000 | 7 | 184 | −174 | |
| Other expense ( income) | −23,000 | 59,000 | 202,000 | −102,000 | −173,000 | |
| Total other expense, net | −776,000 | −4 | 15 | 211 | −245 | |
| Net Loss | −69 | −79 | −60 | 142 | −302 | |
| Unrealized gain on marketable securities | 69,000 | 11,000 | 667,000 | −466,000 | −212,000 | |
| Total other comprehensive income | 69,000 | 11,000 | 667,000 | −466,000 | −212,000 | |
| Total comprehensive loss | −69 | −79 | −60 | 142 | −303 | |
| Basic net loss per common share | −1.66 | −2.5 | −0.11 | 0.3 | −0.72 | |
| Basic weighted-average shares outstanding | 42 | 31 | 568 | 468 | 422 | |
| Diluted net loss per common share | −1.66 | −2.5 | −0.11 | −0.11 | −0.72 | |
| Diluted weighted-average shares outstanding | 42 | 31 | 568 | 618 | 422 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 40 | 75 | 76 | 36 | 33 | |
| Restricted cash | 315,000 | 315,000 | — | — | — | |
| Short term investments, net | 54 | — | 34 | 108 | 96 | |
| Inventory, net | 7 | 4 | 9 | 7 | 6 | |
| Prepaid expenses and other current assets | 4 | 6 | 7 | 7 | 6 | |
| Total current assets | 118 | 91 | 130 | 161 | 144 | |
| Deposits and other assets | 5 | 5 | 7 | 3 | 1 | |
| Property, equipment and intangible assets, net | 4 | 4 | 1 | — | — | |
| Total assets | 126 | 100 | 138 | 178 | 199 | |
| Accounts payable | 4 | 3 | 5 | 419,000 | 1 | |
| Accrued expenses and other current liabilities | 20 | 16 | 13 | 15 | 11 | |
| Note payable, current portion, net | — | 20 | — | 16 | — | |
| Total current liabilities | 24 | 39 | 17 | 31 | 18 | |
| Long-term debt and notes payables, net | 36 | 35 | 41 | 56 | 60 | |
| Non-current operating lease liabilities | 5 | 6 | 6 | — | — | |
| Total liabilities | 65 | 79 | 65 | 143 | 384 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock and additional paid-in-capital, subject to possible redemption: $0.001 par value per share; 0 shares and 12,000 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | 38 | 38 | 38 | — | |
| Total temporary equity | — | 38 | 38 | 38 | — | |
| Common stock, $0.001 par value per share; 70,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 41,265,778 shares and 29,767,561 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 41,000 | 30,000 | 530,000 | 480,000 | 447,000 | |
| Additional paid-in capital | 1,078 | 931 | 905 | 806 | 765 | |
| Accumulated other comprehensive income | 69,000 | — | −11,000 | −678,000 | −212,000 | |
| Accumulated deficit | −1,000 | −948 | −869 | −809 | −951 | |
| Total stockholders' equity (deficit) | 61 | −17 | 36 | −3 | −186 | |
| Total liabilities, temporary equity and stockholders' equity (deficit) | 126 | 100 | 138 | 178 | 199 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −69 | −79 | −60 | 142 | −302 | |
| Depreciation and amortization expense | 2 | 1 | 1 | 985,000 | 1 | |
| Non-cash interest expense (debt discount and deferred costs) | 1 | 4 | 7 | 12 | 8 | |
| Net amortization of premiums and accretion of discounts on marketable securities | −1 | −1 | −3 | — | — | |
| Gain on change in fair value of derivatives | — | −102,000 | −7 | −184 | 174 | |
| Stock-based compensation expense | 10 | 9 | 9 | 9 | 9 | |
| Provision for inventory obsolescence and losses | 694,000 | 4 | 174,000 | — | — | |
| Allowance for credit losses | 931,000 | 220,000 | — | — | — | |
| Accounts receivable | −7 | −3 | −2 | −478,000 | 1 | |
| Prepaid expenses and other current assets | 1 | 1 | 162,000 | −1 | −2 | |
| Inventory | −3 | 696,000 | −2 | −989,000 | −1 | |
| Deposits and other assets | 13,000 | 2 | −438,000 | 381,000 | −164,000 | |
| Accounts payable | 1 | −2 | 2 | −785,000 | −559,000 | |
| Accrued expenses and other liabilities | 5 | 3 | −1 | 1 | 2 | |
| Accrued interest | −490,000 | 86,000 | 31,000 | −95,000 | 372,000 | |
| Payments on lease liabilities | −939,000 | −912,000 | −1 | — | — | |
| Net cash used in operating activities | −59 | −60 | −70 | −66 | −56 | |
| Capital expenditures | −1 | −2 | −350,000 | −312,000 | −210,000 | |
| Purchase of marketable securities | −101 | −58 | −69 | −105 | −155 | |
| Proceeds from sale and maturity of marketable securities | 48 | 93 | 159 | 132 | 6 | |
| Net cash (used in) provided by investing activities | −53 | 33 | 90 | 27 | −149 | |
| Proceeds from exercise of stock options, RSUs and ESPP issuances, net | 143,000 | 179,000 | 73,000 | 1 | — | |
| Proceeds from issuance of term loan, net | — | 10 | 24 | — | — | |
| Taxes paid related to net share settlement of equity awards | −2 | −2 | −3 | −3 | −5 | |
| Repayment of 2025 Notes | −20 | — | — | — | — | |
| Proceeds from issuance of the RD Shares and the PP Warrants | — | 15 | — | — | — | |
| Payment of debt modification costs | −412,000 | — | — | — | — | |
| Net cash provided by financing activities | 78 | 27 | 20 | 42 | 220 | |
| Net decrease in cash and cash equivalents | −34 | −797,000 | 40 | 2 | 15 | |
| Cash paid during the period for interest | 4 | 5 | 4 | 7 | 8 | |
| Issuance of common stock converted from preferred shares | 30 | — | — | — | — | |
| Property and equipment purchases included in accounts payable and accrued expenses | 54,000 | 418,000 | 173,000 | — | 30,000 | |
| Issuance of warrants for Loan and Security Agreement | — | 149,000 | 364,000 | — | — | |
| Change in exercise price of warrants due to Amended Loan and Security Agreement | −163,000 | — | — | — | — | |
| Acquisition of sensor insertion network assets in exchange for accounts receivable | — | 725,000 | — | — | — | |
| Liabilities for contingent consideration | — | 50,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Senseonics Holdings, Inc.'s CIK number?
Senseonics Holdings, Inc.'s SEC CIK number is 0001616543 (1616543). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Senseonics Holdings, Inc.'s SEC filings?
All of Senseonics Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Senseonics Holdings, Inc. last report earnings?
Senseonics Holdings, Inc. (SENS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-057142). This is Senseonics Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Senseonics Holdings, Inc.'s most recent earnings 8-K?
Senseonics Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-057142. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Senseonics Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →